Fierce Pharma6d
FDA rejects Hengrui, Elevar's PD-1 cancer drug combination—again
Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...
Nature4y
PharmAbcine: building a pipeline of oncology antibody therapeutics
The VEGF/VEGFR-2 pathways are central to angiogenesis, the process through which blood vessels that support the growth of colon, lung, breast and renal tumors are formed. Approved drugs including ...
The Pharma Letter3d
FDA again rejects Hengrui and Elevar’s liver cancer combo
US regulators have once again declined to approve Hengrui Pharmaceuticals' (SHA: 600276) PD-1 inhibitor camrelizumab, further delaying the drug's entry into the American market.
Targeted Oncology10h
VXM01 Plus Avelumab Shows Safety, Tolerability in Recurrent Glioblastoma
Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.
Medscape5d
Sequential Therapy in Metastatic Clear Cell Renal Carcinoma
test for pathway- and/or specific drug metabolism-related SNPs Dose/schedule alterations; crossover to a VEGFR–TKI with narrower specificity; sequential treatment with immunotherapy (if slowly ...